Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.

Millot, Frédéric

Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. [electronic resource] - Journal of clinical oncology : official journal of the American Society of Clinical Oncology Jul 2011 - 2827-32 p. digital

Publication Type: Clinical Trial, Phase IV; Journal Article; Multicenter Study

1527-7755

10.1200/JCO.2010.32.7114 doi


Adolescent
Antineoplastic Agents--adverse effects
Benzamides
Child
Child, Preschool
Disease-Free Survival
Dose-Response Relationship, Drug
Drug-Related Side Effects and Adverse Reactions
France
Humans
Imatinib Mesylate
Infant
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Piperazines--adverse effects
Prospective Studies
Pyrimidines--adverse effects
Survival Analysis